Kissei Pharmaceutical Balance Sheet

Financials in millions JPY. Fiscal year is April - March.

Millions JPY. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Cash & Equivalents	30,635	29,057	25,169	22,894	25,893	30,013
Short-Term Investments	22,319	25,367	23,485	23,039	23,706	23,139
Cash & Short-Term Investments	52,954	54,424	48,654	45,933	49,599	53,152
Cash Growth	8.62%	11.86%	5.92%	-7.39%	-6.69%	19.57%
Receivables	27,800	30,761	28,951	27,790	22,083	21,956
Inventory	25,802	25,521	24,979	26,296	22,798	18,987
Other Current Assets	3,667	4,263	4,396	4,532	6,161	5,247
Total Current Assets	110,223	114,969	106,980	104,551	100,641	99,342
Property, Plant & Equipment	27,722	28,093	27,069	24,861	24,579	24,074
Long-Term Investments	129,613	129,513	107,544	128,910	94,034	112,574
Goodwill	-	176	242	309	-	-
Other Intangible Assets	2,157	1,793	1,652	1,683	1,507	1,569
Long-Term Deferred Tax Assets	522	538	566	608	433	524
Other Long-Term Assets	3	-	1	2	1	1
Total Assets	270,240	275,086	244,059	260,929	221,200	238,087
Accounts Payable	5,248	6,661	4,602	4,893	4,617	4,104
Accrued Expenses	880	2,298	2,192	1,856	1,679	1,721
Short-Term Debt	1,250	1,250	1,280	1,340	1,490	1,640
Current Income Taxes Payable	1,278	5,006	1,474	2,380	408	3,497
Other Current Liabilities	9,634	6,473	7,030	7,194	6,763	7,782
Total Current Liabilities	18,290	21,688	16,578	17,663	14,957	18,744
Pension & Post-Retirement Benefits	201	220	202	209	192	181
Long-Term Deferred Tax Liabilities	20,702	21,029	16,481	21,188	10,426	16,259
Other Long-Term Liabilities	602	614	673	735	812	724
Total Liabilities	39,795	43,551	33,934	39,795	26,387	35,908
Common Stock	24,356	24,356	24,356	24,356	24,356	24,356
Additional Paid-In Capital	24,243	24,243	24,226	24,226	24,226	24,226
Retained Earnings	136,831	136,253	131,488	127,310	125,576	118,183
Treasury Stock	-15,514	-15,513	-14,520	-13,209	-12,912	-12,912
Comprehensive Income & Other	59,117	60,806	43,453	57,344	32,653	47,532
Total Common Equity	229,033	230,145	209,003	220,027	193,899	201,385
Minority Interest	1,412	1,390	1,122	1,107	914	794
Shareholders' Equity	230,445	231,535	210,125	221,134	194,813	202,179
Total Liabilities & Equity	270,240	275,086	244,059	260,929	221,200	238,087
Total Debt	1,250	1,250	1,280	1,340	1,490	1,640
Net Cash (Debt)	51,704	53,174	47,374	44,593	48,109	51,512
Net Cash Growth	8.91%	12.24%	6.24%	-7.31%	-6.61%	20.61%
Net Cash Per Share	1247.32	1279.38	1086.01	985.30	1043.24	1117.03
Filing Date Shares Outstanding	41.45	41.45	41.44	44.21	45.96	46.12
Total Common Shares Outstanding	41.45	41.45	42.81	44.21	46.12	46.12
Working Capital	91,933	93,281	90,402	86,888	85,684	80,598
Book Value Per Share	5525.27	5552.08	4882.67	4977.38	4204.63	4366.94
Tangible Book Value	226,876	228,176	207,109	218,035	192,392	199,816
Tangible Book Value Per Share	5473.23	5504.58	4838.42	4932.32	4171.95	4332.92
Order Backlog	-	1,899	3,403	2,613	2,098	1,479